Teva drugs help boost Mayne revenue

Teva drugs help boost Mayne revenue


The $US652 million acquisition of a suite of generic drugs from Teva Pharmaceutical Industries has helped Mayne Pharma to a strong start to the financial year. Mayne Pharma chief executive Scott Richards told shareholders at the company's annual general meeting on Tuesday that group revenue to the end of October had more than doubled to $172 million compared to a year ago.



from Biotech News